Safety Data Sheet

Section 1: Identification

Product identifier
Product Name • Pyridostigmine bromide tablets, 60 mg
Product Code • 368682302103; NDC 68682-302-10

Relevant identified uses of the substance or mixture and uses advised against
Recommended use • Pyridostigmine Bromide Tablets are useful in the treatment of myasthenia gravis.

Details of the supplier of the safety data sheet
Manufacturer • Valeant Pharmaceuticals International, Inc.
2150 St. Elzear West
Laval H7L 4A8
Canada
valeant.com

Supplier • Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals N. America, LLC
400 Somerset Corporate Blvd.
Bridgewater, NJ 08807
United States
valeant.com

Emergency telephone number
Manufacturer • 1-800-535-5053 - US - Infotrac
Manufacturer • +1 352-323-3500 - International - Infotrac

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to consumer use of the product.

Section 2: Hazard Identification

United States (US)
According to: OSHA 29 CFR 1910.1200 HCS

Classification of the substance or mixture
OSHA HCS 2012 • Acute Toxicity Oral 3

Label elements
OSHA HCS 2012

DANGER

Hazard statements • Toxic if swallowed
Precautionary statements
Prevention • Wash thoroughly after handling. Do not eat, drink or smoke when using this product. Do not handle until all safety precautions have been read and understood.

Response • IF SWALLOWED: Immediately call a POISON CENTER/doctor/. Specific treatment, see supplemental first aid information. Rinse mouth.

Storage/Disposal • Store refrigerated, 2-8°C (36-46°F) to maintain product integrity. Protect from light. Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

Other hazards
OSHA HCS 2012 • No data available

Section 3 - Composition/Information on Ingredients

Substances

• Material does not meet the criteria of a substance according to United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

Mixtures

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Identifiers</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colloidal silicon dioxide</td>
<td>CAS:7631-86-9</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>EINECS:231-545-4</td>
<td></td>
</tr>
<tr>
<td>Lactose</td>
<td>CAS:63-42-3</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>EINECS:200-559-2</td>
<td></td>
</tr>
<tr>
<td>Pyridostigmine bromide</td>
<td>CAS:101-26-8</td>
<td>16.32%</td>
</tr>
<tr>
<td></td>
<td>EINECS:202-929-9</td>
<td></td>
</tr>
<tr>
<td>Stearic acid</td>
<td>CAS:57-11-4</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>EINECS:200-313-4</td>
<td></td>
</tr>
</tbody>
</table>

N/A - Designates that the chemical percentage of composition is not available as it is considered a trade secret.

Section 4: First-Aid Measures

Description of first aid measures

Inhalation • Normal use of this product does not pose an inhalation hazard. However, during bulk handling should respiratory tract irritation develop, discontinue use and remove to fresh air. Get medical attention if irritation or other symptoms develop or persist.

Skin • No specific treatment is necessary since this material is not likely to be hazardous by contact with the skin or mucous membranes. Immediately flush skin with large amounts of water. Remove contaminated clothing. If irritation (redness, rash, blistering) develops, get medical attention.

Eye • Hold eye open and rinse slowly and gently with water for 15-20 minutes. Remove contact lenses, if present, after the first five minutes, then continue rinsing eye. Get medical attention immediately if symptoms occur.

Ingestion • If swallowed, seek medical advice immediately and show this container or label.

Most important symptoms and effects, both acute and delayed
As is true of all cholinergic drugs, overdosage of pyridostigmine bromide extended-release tablets may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death.

**Indication of any immediate medical attention and special treatment needed**

**Notes to Physician**
- Treat according to accepted protocols. For additional guidance, refer to the current prescribing information.

**Antidotes**
- The immediate use of atropine in cholinergic crisis is recommended.

### Section 5: Fire-Fighting Measures

**Extinguishing media**

**Suitable Extinguishing Media**
- Water spray, carbon dioxide, dry chemical powder or appropriate foam for surrounding fire.

**Unsuitable Extinguishing Media**
- No data available

**Special hazards arising from the substance or mixture**

**Unusual Fire and Explosion Hazards**
- No data available

**Hazardous Combustion Products**
- No data available.

**Advice for firefighters**
- As in any fire, wear self-contained breathing apparatus and full protective gear to prevent contact with skin and eyes.

### Section 6 - Accidental Release Measures

**Personal precautions, protective equipment and emergency procedures**

**Personal Precautions**
- No special controls or personal protection required under conditions of intended use. In the event of bulk spills, wear suitable protective eyewear, clothing, protective boots and protective gloves. Evacuate immediate area. Ensure adequate ventilation. Refer to Section 8.

**Emergency Procedures**
- Keep unauthorized personnel away. Clean up spilled tablets and place in sealed container. Avoid breaking tablets or creating dust during clean up.

**Environmental precautions**
- No data available on the environmental impact of this product.

**Methods and material for containment and cleaning up**

**Containment/Clean-up Measures**
- LARGE SPILLS: Use HEPA vacuum to clean up spill. If HEPA vacuum is not available, dampen spilled tablets with water prior to cleaning up to prevent dust cloud.

### Section 7 - Handling and Storage

**Precautions for safe handling**

**Handling**
- Avoid breaking or crushing tablets. Minimize dust generation and accumulation. Use good safety and industrial hygiene practices.

**Conditions for safe storage, including any incompatibilities**

**Storage**
- Keep tightly closed. Store between 2-8ºC (36-46ºF), to maintain product integrity. Use before expiration date marked on carton and/or container. Protect from light.

### Section 8 - Exposure Controls/Personal Protection
Control parameters

Exposure Limits/Guidelines • Refer to the occupational exposure limits / guidelines for the individual product components.

Exposure controls

Engineering Measures/Controls • NO SPECIAL CONTROLS ARE REQUIRED UNDER CONDITIONS OF INTENDED USE. Local exhaust ventilation should be provided when handling bulk product.

Personal Protective Equipment Respiratory • For bulk handling, the personal breathing protection should be determined based upon a risk assessment and in accordance with local regulations. Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or symptoms are experienced.

Eye/Face • Wear protective eyewear (goggles, face shield, or safety glasses) when handling bulk product before closed in final packaging.

Hands • Wear protective gloves when handling bulk product before closed in final packaging.

Skin/Body • Avoid contact with skin.

General Industrial Hygiene Considerations • Handle in accordance with good industrial hygiene and safety practice. Wash thoroughly with soap and water after handling.

Environmental Exposure Controls • No data available

Section 9 - Physical and Chemical Properties

Information on Physical and Chemical Properties

<table>
<thead>
<tr>
<th>Material Description</th>
<th>Physical Form</th>
<th>Appearance/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Solid</td>
<td>white, round tablets imprinted with &quot;PBT&quot;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>General Properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boiling Point</td>
</tr>
<tr>
<td>Melting Point/Freezing Point</td>
</tr>
<tr>
<td>Decomposition Temperature</td>
</tr>
<tr>
<td>pH</td>
</tr>
<tr>
<td>Specific Gravity/Relative Density</td>
</tr>
<tr>
<td>Density</td>
</tr>
<tr>
<td>Water Solubility</td>
</tr>
<tr>
<td>Viscosity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Volatility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapor Pressure</td>
</tr>
<tr>
<td>Evaporation Rate</td>
</tr>
<tr>
<td>Vapor Density</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Flammability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flash Point</td>
</tr>
<tr>
<td>UEL</td>
</tr>
<tr>
<td>LEL</td>
</tr>
<tr>
<td>Autoignition</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Environmental</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octanol/Water Partition coefficient</td>
</tr>
</tbody>
</table>

Section 10: Stability and Reactivity

Reactivity • Stable under normal temperatures and pressures.
Chemical stability

- Hazardous polymerization will not occur.

Possibility of hazardous reactions

- No data available

Conditions to avoid

- Light, heat and humidity.

Incompatible materials

- Strong oxidizing agents.

Hazardous decomposition products

- When heated to decomposition, toxic fumes of nitrous oxides, sulfur oxides, hydrogen chloride and carbon oxides may be emitted.

Section 11 - Toxicological Information

Information on toxicological effects

<table>
<thead>
<tr>
<th>Components</th>
<th>Acute Toxicity: Ingestion/Oral-Mouse LD50 • 16 mg/kg; Sense Organs and Special Senses:Eye:Miosis (pupillary constriction); Behavioral:Somnolence (general depressed activity); Lungs, Thorax, or Respiration:Respiratory stimulation; Ingestion/Oral-Rat LD50 • 37500 µg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyridostigmine bromide (16.32%)</td>
<td>101-26-8</td>
</tr>
</tbody>
</table>

GHS Properties

<table>
<thead>
<tr>
<th>Classification</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute toxicity</td>
<td>OSHA HCS 2012 • Acute Toxicity - Oral 3</td>
</tr>
<tr>
<td>Skin corrosion/Irritation</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Serious eye damage/Irritation</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Skin sensitization</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Respiratory sensitization</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Aspiration Hazard</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Carcinogenicity</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Germ Cell Mutagenicity</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>Toxicity for Reproduction</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>STOT-SE</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
<tr>
<td>STOT-RE</td>
<td>OSHA HCS 2012 • Classification criteria not met</td>
</tr>
</tbody>
</table>

Potential Health Effects

Inhalation

- **Acute (Immediate)**: Under normal conditions of use, no health effects are expected. Exposure to dust from broken tablets may cause irritation.

- **Chronic (Delayed)**: Repeated and prolonged exposure may cause irritation.

Skin

- **Acute (Immediate)**: Under normal conditions of use, no health effects are expected.

- **Chronic (Delayed)**: Repeated and prolonged exposure may cause irritation.

Eye

- **Acute (Immediate)**: May cause mild eye irritation with direct contact to eye.
Chronic (Delayed) • Under normal conditions of use, no health effects are expected.

Ingestion

Acute (Immediate) • Toxic if ingested in excess of prescription dose.

Chronic (Delayed) • No data available

Section 12 - Ecological Information

Toxicity • This material has not been tested for environmental effects.

Persistence and degradability • No data available

Bioaccumulative potential • No data available

Mobility in Soil • No data available

Other adverse effects

Section 13 - Disposal Considerations

Waste treatment methods

Product waste • Waste characterizations and compliance with applicable laws are the responsibility solely of the waste generator.

Packaging waste • Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

Section 14 - Transport Information

<table>
<thead>
<tr>
<th>UN number</th>
<th>UN proper shipping name</th>
<th>Transport hazard class(es)</th>
<th>Packing group</th>
<th>Environmental hazards</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT</td>
<td>UN3249</td>
<td>MEDICINE, SOLID, TOXIC, N.O.W. (PYRIDOSTIGMINE BROMIDE)</td>
<td>6.1</td>
<td>III</td>
</tr>
<tr>
<td>DOT</td>
<td>ID8000</td>
<td>Limited Quantity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TDG</td>
<td>UN3249</td>
<td>MEDICINE, SOLID, TOXIC, N.O.S. (PYRIDOSTIGMINE BROMIDE)</td>
<td>6.1</td>
<td>III</td>
</tr>
<tr>
<td>IMO/IMDG</td>
<td>UN3249</td>
<td>MEDICINE, SOLID, TOXIC, N.O.S. (PYRIDOSTIGMINE BROMIDE)</td>
<td></td>
<td>III</td>
</tr>
<tr>
<td>IATA/ICAO</td>
<td>UN3249</td>
<td>MEDICINE, SOLID, TOXIC, N.O.S. (PYRIDOSTIGMINE BROMIDE)</td>
<td>6.1</td>
<td>III</td>
</tr>
<tr>
<td>IATA/ICAO</td>
<td>ID8000</td>
<td>Limited Quantity</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Special precautions for user • No data available

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code • No data available

Other information
DOT • This product may be shipped as a limited quantity as shown above. It may also be shipped as a Consumer Commodity ORM-D in the US. DOT 49 CFR 173.153(B) or (c).

TDG • Within Canada, the Limited Quantity Exemption may apply for containers which hold 5 kg or less of the product. A combination package with a maximum gross weight of 30 kg must be used. Refer to TDGR Section 1.17.

IATA/ICAO • In final packaging this product may be shipped as a Limited Quantity (ID8000).

Section 15 - Regulatory Information

Safety, health and environmental regulations/legislation specific for the substance or mixture

SARA Hazard Classifications • No data available

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS</th>
<th>Canada DSL</th>
<th>Canada NDSL</th>
<th>EU EINECS</th>
<th>TSCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyridostigmine bromide</td>
<td>101-26-8</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Canada

Labor

Canada - WHMIS - Classifications of Substances

• Pyridostigmine bromide

Canada - WHMIS - Ingredient Disclosure List

• Pyridostigmine bromide

United States - California

Environment

U.S. - California - Proposition 65 - Carcinogens List

• Pyridostigmine bromide

U.S. - California - Proposition 65 - Developmental Toxicity

• Pyridostigmine bromide

U.S. - California - Proposition 65 - Reproductive Toxicity - Female

• Pyridostigmine bromide

U.S. - California - Proposition 65 - Reproductive Toxicity - Male

• Pyridostigmine bromide

Section 16 - Other Information

Revision Date • 16/November/2016
Last Revision Date • 16/November/2016
Preparation Date • 16/November/2016
Disclaimer/Statement of Liability • To the best of our knowledge, the information contained herein is accurate. However, neither Valeant Pharmaceuticals International, Inc. nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. NO WARRANTY, EXPRESS OR
IMPLIED, OF MERCHANTABILITY, FITNESS OR OTHERWISE IS MADE. In no event shall Valeant Pharmaceuticals International, Inc. or any of its subsidiaries be liable for any special, incidental or consequential damages.